The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]).

The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes.

It is designed to protect against any of the four serotypes.

Qdenga is claimed to be the only dengue vaccine approved in the UK to prevent dengue fever, regardless of previous exposure. It needs to be utilised as per the official recommendations.

Takeda UK & Ireland medical director Simon Meadowcroft said: “We are pleased to announce this latest regulatory approval which provides the opportunity for the nearly five million (4.6) UK travellers who visit dengue endemic regions every year to protect themselves from infection with this disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Dengue is a complex and widespread disease with half the world’s population living in endemic areas.

“The launch of Qdenga means that for the first time, those living in the UK and travelling to dengue-endemic countries have the option of being vaccinated against infection.”

The regulatory approval is based on data obtained from the ongoing Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.

The placebo-controlled, randomised, double-blind trial assessed the immunogenicity, safety, and efficacy of the dengue tetravalent vaccine.

It evaluated a two-dose schedule of the vaccine in over 20,000 healthy children and dengue-naive children aged four to 16 years who have been living in dengue-endemic areas for over three years.

The company intends to seek recommendations from Joint Committee on Vaccination and Immunisation (JCVI) for Qdenga this year.